Skip to main content
AHG logo

AHG · Akso Health Group

$1.60 +0.02 (+1.27%) At close · Jul 21
Market Cap
$1.37B
Shares
856.70M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.60 Open$1.53 Day$1.53–1.60 52W$1.10–2.50 Avg vol 30d13K Short int29K · 0.0% float · 1.5d Short vol12% DataJan 2020–Jul 2026

Up next

FQ2-27 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 17.1 · elevated Equity put/call 0.65
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg +5%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 36%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +19%
trailing
6-month return +12%
trailing
YTD return −2%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+20% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · ▲ +13.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 3-yr range
Squeeze score 30
low risk · 0–100
Fundamentals
Strong
Revenue growth +512%
Y/Y
Gross margin -2%
contracting
EPS growth −129%
Y/Y
Free cash flow $1.0M
Buyback $25.0M
authorized
Balance sheet $176.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −54%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
+5% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
36% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+20% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.00% of float · ▲ +13.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1 Now $2 · 36% 52-wk high $3
vs 200-day avg -3% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Distribution — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AHG
Akso Health Group
this stock
$1.37B -2.4% +119.7% 0.0%
MCK
Mckesson Corp
$99.63B +1.1% +3.1% 21.6 3.4%
COR
Cencora, Inc.
$58.97B -10.1% +9.3% 23.2 2.8%
CAH
Cardinal Health Inc
$53.44B +11.1% -1.9% 3.0%
HSIC
Henry Schein Inc
$9.78B +13.6% +5.9% 25.9 6.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
6
% held
0.0%
Net QoQ
+52.7K sh
Top holder
RENAISSANCE TECHNOLOGIES…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
29.3K
Days to cover
1.5d
Change
+3.5K sh
View
Short Volume
Short vol %
12%
As of
Jul 21, 2026
Short Total
View
Fails to Deliver
FTD shares
48
Value
$70
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
25.7%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$14.8M
Net income (FY)
$-135.0M
EPS diluted
$-0.16
View
Buybacks
Authorized
$25.0M
View
Filings
SEC Filings
Latest
6-K
Filed
May 13, 2026
This year
3
View

Performance

5D 20D 120D MTD YTD
AHG +5.3% +19.4% +11.9% +7.4% -2.4%
SPY -0.5% +0.5% +7.6% +0.2% +9.7%
vs SPY +5.7% +18.9% +4.3% +7.2% -12.2%

Capital returns

Buyback program · as of Dec 10, 2018
Authorized
$25.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1702318 CUSIP 98422P108 Visit website